Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Agenus, a biotechnology company, has signed a deal with NewVac, a subsidiary of ChemRar over development and manufacturing technology transfer agreement for Agenus' Oncophage (HSPPC-96; vitespen) vaccine.
Subscribe to our email newsletter
Under the terms of the deal, Agenus has granted NewVac an exclusive license to manufacture, market and sell Oncophage as well as pursue a development program of Oncophage in combination with NewVac’s co-adjuvant technology in the Russian Federation and CIS countries.
Agenus will receive a transfer price and royalties upon Oncophage product sales, and potential milestone payments.
Oncophage is approved in Russia for the treatment of renal cell carcinoma in patients who have intermediate risk of recurrence.